M. Kasembeli

发表

Chemical Probes that Competitively and Selectively Inhibit Stat3 Activation

D. Tweardy, Xuejun Xu, M. Kasembeli, 2009, PloS one.

Rhodium(II) Proximity-Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Anti-Leukemia Activity.

Wei Liu, D. Tweardy, M. Kasembeli, 2015, Angewandte Chemie.

Pharmacokinetics (PK) and pharmacodynamics (PD) of TTI-101, a STAT3 inhibitor that blocks muscle proteolysis in rats with chronic kidney disease.

W. Mitch, D. Tweardy, Liping Zhang, 2020, American journal of physiology. Renal physiology.

Blockade of the PD-1/PD-L1 Immune Checkpoint Pathway Improves Infection Outcomes and Enhances Fungicidal Host Defense in a Murine Model of Invasive Pulmonary Mucormycosis

M. Kasembeli, D. Kontoyiannis, J. Tarrand, 2022, Frontiers in Immunology.

Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution

D. Tweardy, M. Kasembeli, P. Robinson, 2020, Pharmacological Reviews.

DRUG-REPOSITIONING SCREENING IDENTIFIED PIPERLONGUMINE AS A DIRECT STAT3 INHIBITOR WITH POTENT ACTIVITY AGAINST BREAST CANCER

C. Creighton, Jenny C. Chang, D. Tweardy, 2014, Oncogene.

Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment

D. Tweardy, M. Kasembeli, P. Robinson, 2018, International journal of molecular sciences.

Chaperonin TRiC/CCT Recognizes Fusion Oncoprotein AML1-ETO through Subunit-Specific Interactions.

Jesús G. Galaz-Montoya, W. Chiu, D. Tweardy, 2016, Biophysical journal.

Chaperonin TRiC/CCT Modulates the Folding and Activity of Leukemogenic Fusion Oncoprotein AML1-ETO*

Jesús G. Galaz-Montoya, W. Chiu, A. Burlingame, 2015, The Journal of Biological Chemistry.

Contribution of the Type II Chaperonin, TRiC/CCT, to Oncogenesis

W. Chiu, Deenadayalan Bakthavatsalam, D. Tweardy, 2015, International journal of molecular sciences.

Contribution of chaperones to STAT pathway signaling.

D. Tweardy, M. Kasembeli, Moses M. Kasembeli, 2014, JAK-STAT.

Modulation of STAT3 Folding and Function by TRiC/CCT Chaperonin

W. Chiu, J. Frydman, W. Lau, 2014, PLoS biology.

Protein stabilization improves STAT3 function in autosomal dominant hyper-IgE syndrome.

O. Lichtarge, D. Tweardy, Panagiotis Katsonis, 2016, Blood.

PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2.

Steven H. Lin, Junjie Chen, D. Tweardy, 2016, Cell reports.

Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma

Q. Mo, D. Tweardy, Yongcheng Song, 2016, Oncotarget.

Novel STAT3 Small-Molecule Inhibitors Identified by Structure-Based Virtual Ligand Screening Incorporating SH2 Domain Flexibility.

Stephen T. C. Wong, Hong Zhao, D. Tweardy, 2021, Pharmacological research.

Chapter 5 STAT 3 Inhibitors in Cancer : A Comprehensive Update

D. Tweardy, M. Kasembeli, Moses M. Kasembeli, 2016 .

STAT3 Inhibitors in Cancer: A Comprehensive Update

D. Tweardy, M. Kasembeli, Moses M. Kasembeli, 2016 .

Small-molecule targeting of signal transducer and activator of transcription (STAT) 3 to treat non-small cell lung cancer.

D. Tweardy, M. Kasembeli, Moses M. Kasembeli, 2015, Lung cancer.

Monoclonal Antibodies Specific for STAT3β Reveal Its Contribution to Constitutive STAT3 Phosphorylation in Breast Cancer

D. Edwards, D. Tweardy, M. Kasembeli, 2014, Cancers.

Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance

D. Tweardy, M. Kasembeli, P. Robinson, 2016, BioMed research international.

TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain

D. Tweardy, A. Kavelaars, M. Kasembeli, 2021, Biochemical pharmacology.

Targeting STAT3 anti-apoptosis pathways with organic and hybrid organic-inorganic inhibitors.

Wei Liu, D. Tweardy, M. Kasembeli, 2020, Organic & biomolecular chemistry.